Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers

Hillman, Richard J., Garland, Suzanne M., Gunathilake, Manoji P. W., Stevens, Matthew, Kumaradevan, Nirmala, Lemech, Charlotte, Ward, Robyn L., Meagher, Alan, McHugh, Leo, Jin, Fengyi, Carroll, Susan, Goldstein, David, Grulich, Andrew E. and Tabrizi, Sepehr N. (2014) Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. International Journal of Cancer, 135 4: 996-1001. doi:10.1002/ijc.28730


Author Hillman, Richard J.
Garland, Suzanne M.
Gunathilake, Manoji P. W.
Stevens, Matthew
Kumaradevan, Nirmala
Lemech, Charlotte
Ward, Robyn L.
Meagher, Alan
McHugh, Leo
Jin, Fengyi
Carroll, Susan
Goldstein, David
Grulich, Andrew E.
Tabrizi, Sepehr N.
Title Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers
Journal name International Journal of Cancer   Check publisher's open access policy
ISSN 1097-0215
0020-7136
Publication date 2014-08-15
Year available 2014
Sub-type Article (original research)
DOI 10.1002/ijc.28730
Open Access Status
Volume 135
Issue 4
Start page 996
End page 1001
Total pages 6
Place of publication Hoboken NJ, United States
Publisher John Wiley & Sons
Collection year 2015
Language eng
Abstract Human papillomavirus (HPV) causes most cases of anal cancers. In this study, we analyzed biopsy material from 112 patients with anal cancers in Australia for the presence of HPV DNA by the INNO LiPA HPV genotyping assay. There were 82% (92) males and 18% (20) females. The mean age at diagnosis was significantly (p = 0.006) younger for males (52.5 years) than females (66 years). HIV-infected males were diagnosed at a much earlier mean age (48.2 years) than HIV negative (56.3 years) males (p = 0.05). HPV DNA was detected in 96.4% (108) of cases. HPV type 16 was the commonest, at 75% (81) of samples and being the sole genotype detected in 61% (66). Overall, 79% (85) of cases had at least one genotype targeted by the bivalent HPV (bHPV) vaccine, 90% (97) by the quadrivalent HPV (qHPV) vaccine and 96% (104) by the nonavalent HPV (nHPV) vaccine. The qHPV vaccine, which is now offered to all secondary school students in Australia, may prevent anal cancers in Australia. However, given the mean age of onset of this condition, the vaccine is unlikely to have a significant impact for several decades. Further research is necessary to prove additional protective effects of the nHPV vaccine.
Keyword HPV
Anal cancer
Australia
Prevalence
Vaccination
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
Office of the Vice-Chancellor
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 11 Feb 2015, 13:34:19 EST by Ms Kate Rowe on behalf of Office of Deputy Vice-Chancellor (Research)